Purpura, Thrombocytopenic
8
1
1
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
ASPirin in Immune thRombocytopenia Patients With Cardiovascular disEase
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry
Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
Atorvastatin in Management of Newly Diagnosed ITP
Drug Etiology of Aplastic Anemia and Related Dyscrasias
Identifying Characteristics of Bone Marrow Failure Syndromes
Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease